JW Pharmaceutical’s ‘Emicizumab’ designated as orphan drug treating hemophilia A

‘Emicizumab,’ a hemophilia A treatment which has been widely known to become a global new drug, has also raised attention of patients as being designated as an orphan drug even in Korea.

JW Pharmaceutical announced on the 21^st that ‘Emicizumab,’ a hemophilia A treatment which secured an exclusive sales approval in Korea from Chugai Pharmaceutical, a subsidiary of Roche Group, was designated by...